<!DOCTYPE html>
<html lang='en'>
  <head>
    <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-PK63DK');</script>
    <meta content='text/html; charset=UTF-8' http-equiv='Content-Type'>
    <meta charset='utf-8'>
    <meta content='width=device-width, initial-scale=1, shrink-to-fit=no' name='viewport'>
    <link crossorigin='anonymous' href='https://stackpath.bootstrapcdn.com/bootstrap/4.1.1/css/bootstrap.min.css' integrity='sha384-WskhaSGFgHYWDcbwN70/dfYBj47jz9qbsMId/iRN3ewGhXQFZCSftd1LZCfmhktB' rel='stylesheet'>
    <link href='/styles.css' rel='stylesheet'>
    <title>60 Degrees Pharmaceuticals to Begin Phase II Clinical Trials</title>
    <script async='async' src='https://www.googletagservices.com/tag/js/gpt.js'></script><script>var googletag=googletag ||{}; googletag.cmd=googletag.cmd || [];</script><script>googletag.cmd.push(function(){googletag.defineSlot('\/1010898\/sgforums_interstitial', [ 1.0 , 1.0], 'div-gpt-ad-1528181032761-0').setTargeting('forum', ['3513']).setTargeting('topic', ['489745']).addService(googletag.pubads()); googletag.defineSlot('\/1010898\/sgforums_leaderboard', [[ 728.0 , 90.0], [ 970.0 , 250.0]], 'div-gpt-ad-1528181032761-1').setTargeting('forum', ['3513']).setTargeting('topic', ['489745']).addService(googletag.pubads()); googletag.defineSlot('\/1010898\/sgforums_mpu', [ 300.0 , 250.0], 'div-gpt-ad-1528181032761-2').setTargeting('forum', ['3513']).setTargeting('topic', ['489745']).addService(googletag.pubads()); googletag.defineSlot('\/1010898\/sgforums_supersky', [ 160.0 , 600.0], 'div-gpt-ad-1528181032761-3').setTargeting('forum', ['3513']).setTargeting('topic', ['489745']).addService(googletag.pubads()); googletag.pubads().enableSingleRequest(); googletag.enableServices();});</script>
  </head>
  <body>
    <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-PK63DK"height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
    <div class='container'>
      <a href='/'>Home</a>
      >
      <a href='/forums/3513/'>PR Newswire Asia</a>
      <h1>60 Degrees Pharmaceuticals to Begin Phase II Clinical Trials</h1>
      <nav class='pagination'>
      </nav>
      <ul class='list-group posts'>
        <li class='list-group-item post'>
          <div class='row'>
            <div class='col-md-2 meta'>
              <div class='author'>Helen.zhang</div>
              <time class='date' datetime='2015-08-24T16:38:42+00:00'>24 Aug 15, 16:38</time>
            </div>
            <div class='col-md body'>
              <div id="dvContent" style="color: #222222; font-family: 'Open Sans', 'Helvetica Neue', Helvetica, Arial, sans-serif; line-height: 23.7999992370605px; font-size: 14px;">
              <p style="font-style: inherit; line-height: 1.7; margin-bottom: 0.825em;"><span class="xn-location" style="font-style: inherit; font-weight: inherit; line-height: 1.7;">WASHINGTON</span> /PRNewswire/ --<strong style="font-style: inherit; line-height: 1.7;"> 60 Degrees Pharmaceuticals, (60P),</strong> a company <strong style="font-style: inherit; line-height: 1.7;">focused on development of therapeutics for tropical diseases,</strong> and Singapore General Hospital (SGH) announced today that the Hospital has received a grant from <span class="xn-location" style="font-style: inherit; font-weight: inherit; line-height: 1.7;">Singapore's</span> National Medical Research Council to support a Phase II clinical trial among dengue fever patients.</p>
              <p style="font-style: inherit; line-height: 1.7; margin-bottom: 0.825em;">Dengue fever, a painful, debilitating and potentially deadly mosquito-borne viral disease, infects an estimated 400 million people worldwide each year, causing 500,000 hospitalizations and creating a <span class="xn-money" style="font-style: inherit; font-weight: inherit; line-height: 1.7;">$12 billion</span> annual burden. Instances of dengue, which cause flu-like symptoms and can develop into lethal severe dengue, have increased 30 fold over the past few decades.</p>
              <p style="font-style: inherit; line-height: 1.7; margin-bottom: 0.825em;">Once believed to be only a "tropical" disease, there have been outbreaks in southern U.S. including <span class="xn-location" style="font-style: inherit; font-weight: inherit; line-height: 1.7;">Florida</span>, as well as in <span class="xn-location" style="font-style: inherit; font-weight: inherit; line-height: 1.7;">France</span>, <span class="xn-location" style="font-style: inherit; font-weight: inherit; line-height: 1.7;">Portugal</span> and other European countries, which experts believe may expand in <span class="xn-location" style="font-style: inherit; font-weight: inherit; line-height: 1.7;">North America</span>and <span class="xn-location" style="font-style: inherit; font-weight: inherit; line-height: 1.7;">Europe</span>. In addition, scientists have discovered a type of dengue-carrying mosquito which can live in colder climates, meaning cases of dengue observed in the U.S. and <span class="xn-location" style="font-style: inherit; font-weight: inherit; line-height: 1.7;">Europe</span> may increase substantially.</p>
              <p style="font-style: inherit; line-height: 1.7; margin-bottom: 0.825em;">There are currently no FDA-approved vaccines or antiviral drugs for dengue virus infection and treatment has been limited to supportive and symptomatic treatment.</p>
              <p style="font-style: inherit; line-height: 1.7; margin-bottom: 0.825em;">60P and SGH will evaluate the safety and effectiveness of an antiviral, Celgosivir, and a disease- modifying agent, Modipafant, in the treatment of dengue.  Earlier animal studies suggest these drugs could prove effective in dengue fever patients. SGH and Duke-NUS Graduate Medical School previously evaluated the efficacy of Celgosivir in dengue patients, establishing its safety.</p>
              <p style="font-style: inherit; line-height: 1.7; margin-bottom: 0.825em;">60P and SGH have received approval from the relevant authority in <span class="xn-location" style="font-style: inherit; font-weight: inherit; line-height: 1.7;">Singapore</span> and Institutional Review Board for the study, which is scheduled to start March 2016.                        </p>
              <p style="font-style: inherit; line-height: 1.7; margin-bottom: 0.825em;"><strong style="font-style: inherit; line-height: 1.7;">About 60 Degrees Pharmaceuticals</strong></p>
              <p style="font-style: inherit; line-height: 1.7; margin-bottom: 0.825em;">60 Degrees Pharmaceuticals, a privately-held company founded in 2010 with a mission to develop small molecule therapeutics for tropical diseases, is focused on development of products with dual use application in the travel medicine market and tropical countries.  The company's development portfolio includes three repositioned dengue therapeutics and an antimalarial drug that has completed Phase III trials.</p>
              <p style="font-style: inherit; line-height: 1.7; margin-bottom: 0.825em;">After executing an exclusive option deal and research agreement with the United States Army in 2014, 60P is preparing for the commercial launch of Tafenoquine for traveler's malaria prophylaxis. Due to its unique mode of action, Tafenoquine also has potential utility for community prophylaxis in malaria-endemic countries in combination with existing control measures. 60P's mission is supported through substantial in kind funding from the United States Department of Defense and other agencies of the U.S. government.  </p>
              <p style="font-style: inherit; line-height: 1.7; margin-bottom: 0.825em;">60 Degrees Pharmaceuticals is headquartered in <span class="xn-location" style="font-style: inherit; font-weight: inherit; line-height: 1.7;">Washington DC</span>, with a subsidiary in Australia.                                                                                    </p>
              <p style="font-style: inherit; line-height: 1.7; margin-bottom: 0.825em;">Further information is available on the Company's website, <a style="color: #1b8be0; font-style: inherit; font-weight: inherit; line-height: 1.7;" rel="nofollow" href="http://www.60degreespharma.com/">www.60degreespharma.com</a>.  </p>
              <p style="font-style: inherit; line-height: 1.7; margin-bottom: 0.825em;"><strong style="font-style: inherit; line-height: 1.7;">For Further Information Contact:<br style="font-style: inherit; font-weight: inherit; line-height: 1.7;"><span class="xn-person" style="font-style: inherit; font-weight: inherit; line-height: 1.7;">Roseann Rosetta</span>, Director, Account Management<br style="font-style: inherit; font-weight: inherit; line-height: 1.7;">Integrated Marketing Services<br style="font-style: inherit; font-weight: inherit; line-height: 1.7;"><a style="color: #1b8be0; font-style: inherit; font-weight: inherit; line-height: 1.7;" rel="nofollow" href="mailto:rrosetta@imsworld.com">rrosetta@imsworld.com</a>    <br style="font-style: inherit; font-weight: inherit; line-height: 1.7;">609-683-9055 x247</strong></p>
              <p style="font-style: inherit; line-height: 1.7; margin-bottom: 0.825em;"><strong style="font-style: inherit; line-height: 1.7;"><span class="xn-person" style="font-style: inherit; font-weight: inherit; line-height: 1.7;">Goeff Dow</span>, CEO, 60 Degrees Pharmaceuticals        <br style="font-style: inherit; font-weight: inherit; line-height: 1.7;"><a style="color: #1b8be0; font-style: inherit; font-weight: inherit; line-height: 1.7;" rel="nofollow" href="mailto:geoffdow@60degreespharma.com">geoffdow@60degreespharma.com</a>  </strong></p>
              </div>
              <div id="dvExtra" style="color: #222222; font-family: 'Open Sans', 'Helvetica Neue', Helvetica, Arial, sans-serif; line-height: 23.7999992370605px; font-size: 14px;"> </div>
              <div id="dvSource" style="color: #222222; font-family: 'Open Sans', 'Helvetica Neue', Helvetica, Arial, sans-serif; line-height: 23.7999992370605px; font-size: 14px;">Source: 60 Degrees Pharmaceuticals</div>
              <div class="dvWebsites" style="color: #222222; font-family: 'Open Sans', 'Helvetica Neue', Helvetica, Arial, sans-serif; line-height: 23.7999992370605px; font-size: 14px;">Related Links:
              <ul style="font-style: inherit; line-height: 1.7; margin: 0px 0px 0.825em 2.5em; list-style: square;">
              <li style="font-style: inherit; font-weight: inherit; line-height: 1.7;"><a style="color: #1b8be0; font-style: inherit; font-weight: inherit; line-height: 1.7;" rel="nofollow" href="http://www.60degreespharma.com/">http://www.60degreespharma.com</a></li>
              </ul>
              </div>
            </div>
          </div>
        </li>
        <li class='list-group-item'>
          <div id='div-gpt-ad-1528181032761-2' style='height:250px; width:300px;'><script>googletag.cmd.push(function(){googletag.display('div-gpt-ad-1528181032761-2');});</script></div>
        </li>
      </ul>
      <nav class='pagination'>
      </nav>
      <footer>
        <nav class='nav'>
          <a class='nav-link' href='/'>Home</a>
          <a class='nav-link' href='/privacy/'>Privacy</a>
          <a class='nav-link' href='/terms/'>Terms</a>
        </nav>
      </footer>
    </div>
    <div id='div-gpt-ad-1528181032761-0' style='height:1px; width:1px;'><script>googletag.cmd.push(function(){googletag.display('div-gpt-ad-1528181032761-0');});</script></div>
  </body>
</html>
